NOVITÀ

What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease Drugs And Therapies?

What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease Drugs And Therapies?

Many pharmaceutical companies are making remarkable progress in their research into candidate treatments for these diseases and 2022 is expected to be yet another eventful year for haemoglobin disorders! Check…
SCD Drug Oxbryta Receives CHMP Positive Opinion For Approval In The EU

SCD Drug Oxbryta Receives CHMP Positive Opinion For Approval In The EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for Oxbryta® (voxelotor) tablets for the treatment of hemolytic…
THALIA 2018-2021: Europe Is Seeing A Surge In Thalassaemia, Project Results Show

THALIA 2018-2021: Europe Is Seeing A Surge In Thalassaemia, Project Results Show

“Although thalassemia has always been endemic in Europe, especially in southern European countries such as Cyprus, Greece and Italy, the disease now knows no borders and constitutes an increasing health,…
The AAC White Paper on Pyruvate Kinase Deficiency Has Just Landed on TIF’s Website

The AAC White Paper on Pyruvate Kinase Deficiency Has Just Landed on TIF’s Website

The White Paper, based on the findings of a large international survey that looked into communication between PKD patients and caregivers and haematologists, also highlights the unmet needs and perceived…
TIF Article: COVID-19 Pandemic Exacerbated Existing Problems With Thalassaemia Care

TIF Article: COVID-19 Pandemic Exacerbated Existing Problems With Thalassaemia Care

The article discusses how the COVID-19 pandemic has magnified challenges in thalassaemia care worldwide and underscores TIF’s activities throughout the coronavirus outbreak in support of patients with haemoglobinopathies. Hematology Advisor…
TIF Guide on COVID-19 Vaccinations & Therapeutic Drugs – The December Issue

TIF Guide on COVID-19 Vaccinations & Therapeutic Drugs – The December Issue

During this last fortnight, experts have scrambled to gain an understanding of the new heavily mutated variant, what kind of symptoms and illness it can cause, and whether it undermines…
FDA Grants Priority Review to Luspatercept-aamt for Anemia in Adults With NTD β-Thalassaemia

FDA Grants Priority Review to Luspatercept-aamt for Anemia in Adults With NTD β-Thalassaemia

The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 27, 2022. In addition, the European Medicines Agency (EMA) has validated the Type II variation…
TIF Signs Agreement With Resonance Health To Deploy FerriSmart®

TIF Signs Agreement With Resonance Health To Deploy FerriSmart®

FerriSmart is an AI-driven system for automated real-time measurement of liver-iron concentrate (LIC) in patients, using non-invasive MRI-based technology. Under the Letter of Agreement, TIF will engage with National Thalassaemia…
La Repubblica: Gene Editing Cured Two Siblings With Thalassaemia In Italy

La Repubblica: Gene Editing Cured Two Siblings With Thalassaemia In Italy

Cured of thalassemia, thanks to gene editing. According to a recent news report published in the Italian newspaper La Repubblica, Erika and Emanuele Guarini, two siblings from Pistoia, Tuscany, aged…
ETA-ESHR Joint Conference 2021

ETA-ESHR Joint Conference 2021

The 22nd Egyptian Thalassaemia Association (ETA) Conference and the 18th Egyptian Society of Hematology and Research (ESHR) Conference will be held jointly starting November 1st until November 4th, 2021. The…
Back to top button